AstPlayer
(Guadecitabine)Phase 2Small molecule
Guadecitabine is used to treat certain types of blood cancers, particularly myelodysplastic syndromes (a condition where bone marrow doesn't make enough healthy blood cells). It works by helping to reactivate genes that have been turned off in cancer cells.[1] AstPlayer is currently being investigated across 6 indications[3], with its most advanced program in Phase 2.[1]
AstPlayer is one of 168 small molecule programs targeting Pembrolizumab. It is currently in Phase 2.
6
Indications
21
Total Trials
7
Active Trials
167
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
206 competitors in Lung Cancer
#DrugCompanyPhaseTrials
1Imfinzi
AstraZenecaPhase 3
Opdivo
Bristol-Myers SquibbPhase 3
Yervoy
Bristol-Myers SquibbPhase 3
Abraxane
Bristol-Myers SquibbPhase 3
Tecentriq
RochePhase 3
Imjudo
AstraZenecaPhase 3
Alunbrig
TakedaPhase 3
DATROWAY
Daiichi SankyoPhase 3
Tarlatamab-Dznl
AmgenPhase 3
Zepzelca
Jazz PharmaceuticalsPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Acute Myeloid Leukemia3 trials
Myelodysplastic Syndromes2 trials
Fallopian Tube Cancer1 trial
Germ Cell Tumor1 trial
13 more indications
Metastatic Colorectal Cancer1 trial
Allogeneic Stem Cell Transplantation1 trial
Gallbladder Cancer1 trial
Kidney Cancer1 trial
Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
Active, not recruiting·—·Phase 1/2·NCT03308396·57 enrolled
Myelodysplastic Syndrome1 trial
Treatment1 trial
Primary Peritoneal Cancer1 trial
Urothelial Carcinoma1 trial
Locally Advanced Unresectable Primary Central Chondrosarcoma1 trial
Lung Cancer1 trial
Chronic Myelomonocytic Leukemia1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Guadecitabine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAstex Pharmaceuticals, Inc.